AAPL332.40-6.00 (-1.77%) ▼|ABBV263.66-2.62 (-0.98%) ▼|ABT99.93-1.05 (-1.04%) ▼|ACN175.22+0.75 (+0.43%) ▲|ADBE231.41+0.40 (+0.17%) ▲|AMAT502.10+15.34 (+3.15%) ▲|AMD612.45+4.58 (+0.75%) ▲|AMGN416.85-1.28 (-0.31%) ▼|AMT167.94-0.07 (-0.04%) ▼|AMZN246.33+0.18 (+0.07%) ▲|AVGO357.83+8.26 (+2.36%) ▲|AXP304.38-1.95 (-0.64%) ▼|BA188.12+3.73 (+2.02%) ▲|BAC54.84-0.63 (-1.14%) ▼|BKNG161.69-2.18 (-1.33%) ▼|BLK1,065.11-6.14 (-0.57%) ▼|BMY63.19-0.69 (-1.08%) ▼|BNY146.85-1.59 (-1.07%) ▼|BRK-B501.21-1.89 (-0.37%) ▼|C130.38-0.93 (-0.71%) ▼|CAT816.72-3.24 (-0.39%) ▼|CL85.85-0.67 (-0.77%) ▼|CMCSA21.54-0.26 (-1.17%) ▼|COF195.60-0.86 (-0.44%) ▼|COP125.89-0.15 (-0.12%) ▼|COST919.23-3.70 (-0.40%) ▼|CRM228.08+0.81 (+0.36%) ▲|CSCO106.36-0.38 (-0.36%) ▼|CVS86.70-1.16 (-1.31%) ▼|CVX204.79-1.58 (-0.77%) ▼|DE681.36-8.23 (-1.19%) ▼|DHR224.08-3.25 (-1.43%) ▼|DIS105.03-0.56 (-0.53%) ▼|DUK113.41+0.00 (+0.00%) ▲|EMR157.06-2.33 (-1.46%) ▼|FDX285.55-4.10 (-1.42%) ▼|GD331.21-2.95 (-0.88%) ▼|GE318.08-0.17 (-0.05%) ▼|GEV957.90+8.13 (+0.86%) ▲|GILD149.65-2.56 (-1.68%) ▼|GM79.81-0.84 (-1.04%) ▼|GOOG335.44-3.72 (-1.10%) ▼|GOOGL338.63-4.12 (-1.20%) ▼|GS905.28-11.00 (-1.20%) ▼|HD288.26-1.63 (-0.56%) ▼|HON210.22-1.30 (-0.61%) ▼|IBM221.99+1.32 (+0.60%) ▲|INTC116.45+0.42 (+0.36%) ▲|INTU266.99-2.41 (-0.89%) ▼|ISRG408.43-6.36 (-1.53%) ▼|JNJ267.01-4.94 (-1.82%) ▼|JPM334.12-2.47 (-0.73%) ▼|KO86.90-0.28 (-0.32%) ▼|LIN472.56+0.52 (+0.11%) ▲|LLY1,174.10-10.68 (-0.90%) ▼|LMT513.63-4.48 (-0.86%) ▼|LOW186.92-0.74 (-0.39%) ▼|LRCX323.17+8.70 (+2.77%) ▲|MA563.15-5.11 (-0.90%) ▼|MCD234.79+1.19 (+0.51%) ▲|MDLZ59.20-0.98 (-1.63%) ▼|MDT87.40-2.10 (-2.35%) ▼|META717.96+2.34 (+0.33%) ▲|MMM168.27-1.21 (-0.71%) ▼|MO68.46-0.68 (-0.98%) ▼|MRK146.90-1.79 (-1.20%) ▼|MS191.65-2.00 (-1.03%) ▼|MSFT509.59+0.37 (+0.07%) ▲|MU1,065.45+11.47 (+1.09%) ▲|NEE75.49+0.00 (+0.00%) ▲|NFLX70.68+1.45 (+2.09%) ▲|NKE35.94-0.46 (-1.25%) ▼|NOW131.43-0.02 (-0.02%) ▼|NVDA230.31+1.45 (+0.63%) ▲|ORCL139.39+6.79 (+5.12%) ▲|PEP127.72-0.78 (-0.61%) ▼|PFE28.27-0.46 (-1.58%) ▼|PG147.85-1.18 (-0.79%) ▼|PLTR186.10-1.38 (-0.74%) ▼|PM191.90-1.87 (-0.96%) ▼|QCOM186.65-0.84 (-0.45%) ▼|RTX187.10-0.57 (-0.30%) ▼|SBUX95.30+0.03 (+0.03%) ▲|SCHW97.47-0.83 (-0.84%) ▼|SO82.75+0.40 (+0.49%) ▲|SPG203.57-0.96 (-0.47%) ▼|T24.74-0.16 (-0.64%) ▼|TMO673.06-5.55 (-0.82%) ▼|TMUS163.11-3.35 (-2.01%) ▼|TSLA354.18-3.27 (-0.91%) ▼|TXN280.84+2.53 (+0.91%) ▲|UBER69.05+0.89 (+1.30%) ▲|UNH372.75-5.09 (-1.35%) ▼|UNP273.46-0.64 (-0.23%) ▼|UPS93.52-0.73 (-0.77%) ▼|USB57.87-0.92 (-1.56%) ▼|V365.41-2.33 (-0.63%) ▼|VZ46.45-0.23 (-0.49%) ▼|WFC80.16-0.66 (-0.81%) ▼|WMT105.87-2.86 (-2.63%) ▼|XOM161.74-0.79 (-0.48%) ▼|AAPL332.40-6.00 (-1.77%) ▼|ABBV263.66-2.62 (-0.98%) ▼|ABT99.93-1.05 (-1.04%) ▼|ACN175.22+0.75 (+0.43%) ▲|ADBE231.41+0.40 (+0.17%) ▲|AMAT502.10+15.34 (+3.15%) ▲|AMD612.45+4.58 (+0.75%) ▲|AMGN416.85-1.28 (-0.31%) ▼|AMT167.94-0.07 (-0.04%) ▼|AMZN246.33+0.18 (+0.07%) ▲|AVGO357.83+8.26 (+2.36%) ▲|AXP304.38-1.95 (-0.64%) ▼|BA188.12+3.73 (+2.02%) ▲|BAC54.84-0.63 (-1.14%) ▼|BKNG161.69-2.18 (-1.33%) ▼|BLK1,065.11-6.14 (-0.57%) ▼|BMY63.19-0.69 (-1.08%) ▼|BNY146.85-1.59 (-1.07%) ▼|BRK-B501.21-1.89 (-0.37%) ▼|C130.38-0.93 (-0.71%) ▼|CAT816.72-3.24 (-0.39%) ▼|CL85.85-0.67 (-0.77%) ▼|CMCSA21.54-0.26 (-1.17%) ▼|COF195.60-0.86 (-0.44%) ▼|COP125.89-0.15 (-0.12%) ▼|COST919.23-3.70 (-0.40%) ▼|CRM228.08+0.81 (+0.36%) ▲|CSCO106.36-0.38 (-0.36%) ▼|CVS86.70-1.16 (-1.31%) ▼|CVX204.79-1.58 (-0.77%) ▼|DE681.36-8.23 (-1.19%) ▼|DHR224.08-3.25 (-1.43%) ▼|DIS105.03-0.56 (-0.53%) ▼|DUK113.41+0.00 (+0.00%) ▲|EMR157.06-2.33 (-1.46%) ▼|FDX285.55-4.10 (-1.42%) ▼|GD331.21-2.95 (-0.88%) ▼|GE318.08-0.17 (-0.05%) ▼|GEV957.90+8.13 (+0.86%) ▲|GILD149.65-2.56 (-1.68%) ▼|GM79.81-0.84 (-1.04%) ▼|GOOG335.44-3.72 (-1.10%) ▼|GOOGL338.63-4.12 (-1.20%) ▼|GS905.28-11.00 (-1.20%) ▼|HD288.26-1.63 (-0.56%) ▼|HON210.22-1.30 (-0.61%) ▼|IBM221.99+1.32 (+0.60%) ▲|INTC116.45+0.42 (+0.36%) ▲|INTU266.99-2.41 (-0.89%) ▼|ISRG408.43-6.36 (-1.53%) ▼|JNJ267.01-4.94 (-1.82%) ▼|JPM334.12-2.47 (-0.73%) ▼|KO86.90-0.28 (-0.32%) ▼|LIN472.56+0.52 (+0.11%) ▲|LLY1,174.10-10.68 (-0.90%) ▼|LMT513.63-4.48 (-0.86%) ▼|LOW186.92-0.74 (-0.39%) ▼|LRCX323.17+8.70 (+2.77%) ▲|MA563.15-5.11 (-0.90%) ▼|MCD234.79+1.19 (+0.51%) ▲|MDLZ59.20-0.98 (-1.63%) ▼|MDT87.40-2.10 (-2.35%) ▼|META717.96+2.34 (+0.33%) ▲|MMM168.27-1.21 (-0.71%) ▼|MO68.46-0.68 (-0.98%) ▼|MRK146.90-1.79 (-1.20%) ▼|MS191.65-2.00 (-1.03%) ▼|MSFT509.59+0.37 (+0.07%) ▲|MU1,065.45+11.47 (+1.09%) ▲|NEE75.49+0.00 (+0.00%) ▲|NFLX70.68+1.45 (+2.09%) ▲|NKE35.94-0.46 (-1.25%) ▼|NOW131.43-0.02 (-0.02%) ▼|NVDA230.31+1.45 (+0.63%) ▲|ORCL139.39+6.79 (+5.12%) ▲|PEP127.72-0.78 (-0.61%) ▼|PFE28.27-0.46 (-1.58%) ▼|PG147.85-1.18 (-0.79%) ▼|PLTR186.10-1.38 (-0.74%) ▼|PM191.90-1.87 (-0.96%) ▼|QCOM186.65-0.84 (-0.45%) ▼|RTX187.10-0.57 (-0.30%) ▼|SBUX95.30+0.03 (+0.03%) ▲|SCHW97.47-0.83 (-0.84%) ▼|SO82.75+0.40 (+0.49%) ▲|SPG203.57-0.96 (-0.47%) ▼|T24.74-0.16 (-0.64%) ▼|TMO673.06-5.55 (-0.82%) ▼|TMUS163.11-3.35 (-2.01%) ▼|TSLA354.18-3.27 (-0.91%) ▼|TXN280.84+2.53 (+0.91%) ▲|UBER69.05+0.89 (+1.30%) ▲|UNH372.75-5.09 (-1.35%) ▼|UNP273.46-0.64 (-0.23%) ▼|UPS93.52-0.73 (-0.77%) ▼|USB57.87-0.92 (-1.56%) ▼|V365.41-2.33 (-0.63%) ▼|VZ46.45-0.23 (-0.49%) ▼|WFC80.16-0.66 (-0.81%) ▼|WMT105.87-2.86 (-2.63%) ▼|XOM161.74-0.79 (-0.48%) ▼|
20.4 C
New York
Tuesday, September 29, 2026

Tag: IT

newssourceFORcompanyinformationcontent1releasesmarket

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.

Epic fantasy strategy game, Elemental returns as Elemental: Reforged

Stardock reforges and integrates War of Magic, Fallen Enchantress and Sorcerer King to fulfill the original vision for Elemental PLYMOUTH, Mich., July 25, 2025 /PRNewswire/ --...

NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups

Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November 
Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November

Movement Room Hits 250 Google 5-Star Reviews, Cementing Position as Best Physiotherapy Clinic in Vancouver

Vancouver, BC, July 25, 2025 (GLOBE NEWSWIRE) -- Movement Room – Physiotherapy East Vancouver proudly announces its latest achievement of 250 5-star reviews on Google, further solidifying its reputation as the best physiotherapy clinic in Vancouver. Conveniently located at 5334 Victoria Dr, Vancouver, BC V5P 3V7, the clinic is known for its expertise in physiotherapy, massage therapy, kinesiology, and ICBC injury rehabilitation, helping thousands of Vancouver residents recover from injuries, manage chronic pain, and restore their physical health.

Matrix Medical Network Announces Strategic Partnership with Molecular Testing Labs to Enhance In-Home Diagnostic Offerings

Leader In Delivering Home-Based Health and Care Services Partners with Laboratory Known for Quality, Reliability and Innovation NASHVILLE, Tenn., July 23, 2025 /PRNewswire/ -- Matrix Medical...

CAPR Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Capricor Therapeutics, Inc. Securities Class Action

Robbins LLP is Investigating Allegations that Capricorn Therapeutics, Inc. (CAPR) Misled Investors Regarding the Viability of Deramiocel

Best Kratom? Super Speciosa Relaunches Enhanced Watermelon Kratom Tincture in 2025

As Consumer Demand Surges for Lab-Tested Botanical Products, Super Speciosa Responds With a Timely Tincture Update and GMP-Backed Transparency 
As Consumer Demand Surges for Lab-Tested Botanical Products, Super Speciosa Responds With a Timely Tincture Update and GMP-Backed Transparency

POP BIO and CEPI announce collaboration for faster responses to Disease X

Buffalo, NY, July 25, 2025 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a biotechnology company specializing in nanoparticle-based vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a new collaboration to accelerate the development of vaccines against future pandemic threats, including a potential ‘Disease X’. Backed by up to $1.5 million in funding from CEPI, the partnership will advance POP BIO’s SNAP™ (Spontaneous Nanoliposome Antigen Particleization) platform—a plug-and-play technology designed to enable rapid-response vaccine development through streamlined protein purification and nanoparticle delivery.

Everlight Solar Named Milwaukee’s Top Choice Winner

MILWAUKEE, July 24, 2025 /PRNewswire/ -- Everlight Solar is honored to announce its recognition as a Milwaukee Top Choice winner for 2025. This community-powered...

#BackToSchool Ready: YITAHOME’s Must-Have Collection

LONDON, July 25, 2025 (GLOBE NEWSWIRE) -- YITAHOME is excited to kick off its #BacktoSchool campaign, unveiling a fresh collection of smart, stylish, and space-saving furniture designed to meet the unique needs of students and families gearing up for the upcoming academic year. Available now on Amazon, this thoughtfully curated collection is all about maximizing space, reducing clutter, and keeping everything organized—without compromising on design or style. Whether it's for a dorm room, apartment, or home office, YITAHOME has the perfect solution for every student’s space.

Spear AI Secures Seed Funding from Scare the Bear Capital and Cortical Ventures to Accelerate Maritime AI Solutions and Expand Technical Services

WASHINGTON, July 25, 2025 /PRNewswire/ -- Spear AI, a leading developer of maritime artificial intelligence solutions, today announced the successful completion of its seed funding...

Neon Bloom, Inc. Announces Successful Launch of AI-Driven Backend Software

Neon Bloom, Inc. Announces Successful Launch of AI-Driven Backend Software

KPN completes € 250m share buyback

Today, KPN announces the completion of its € 250m share buyback, which commenced on 25 February 2025 and was completed on 25 July 2025. In total, KPN has repurchased 62,465,117 ordinary shares at an average price of € 4.00 per share.

Menovelle ‘Coffee Hack’ Fixes Hot Flashes, Belly Weight Gain & Mood Swings, Research Suggests

A Natural Supplement Trend in 2025, Menovelle Helps Women Support Hormonal Balance and Metabolic Energy Without Hormone Therapy or Stimulants 
A Natural Supplement Trend in 2025, Menovelle Helps Women Support Hormonal Balance and Metabolic Energy Without Hormone Therapy or Stimulants

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsIT

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers